Membership

The Dosing Project™ – Establishing evidence-based dosing for Cannabis flower and products derived from analyses of crowd sourced patient responses
Chemotype-based Cultivar Selection for Health & Disease - Determining which plant strains work with which medical diagnosis
Sampling Guidelines for Product Analyses - Recommendations on how to sample cannabis plant and products for quality assurance
Formulation Guidelines for Processed Product Development - Consultations on how to best create your cannabis product

Who should join?

Cannabis Growers & Processors:

Benefit from information reported in all of the above focus areas

Cannabis Health Care Providers & Patients:

Benefit from information reported in 1 and 2 of the above focus areas

Complete the Membership Form below and take a step toward science based medical cannabis products

Become a General Member: ($500 per year)
- Receive reports on Cannabis product cultivation, manufacturing and medical efficacy.
- Receive access to CESC general research results and conclusions 90 days prior to general publication.
- Receive one hour orientation and yearly consultation with CESC Chief Scientific Officer, Chief Medical Officer and Political Science expert.

Become a Sponsoring Member: ($5000 per year)
- Sponsor research and development for specific products
- Receive reports detailing results and conclusions for your specific product [Discounted T&M consultation rates will be applied]
- CESC coordinate clinical research organization and product distribution for study with MediCann
- Study conclusions will be submitted to peer reviewed publications

All members benefit from:
- Webinars, Symposia and Conferences –produced by The CESC
- Sponsorship recognition on our website
- Social Media access linked to The CESC

Contact the CESC for more information

Planned Release Schedule of CESC Quarterly Reports for 2017

End 1Q 2017: Cannabis Flower Sampling Recommendations Derived from Analyses of Cannabinoid and Terpenoid Variance in Test Plots
End 2Q 2017: A Simplified Chemotyping Scheme for Optimal Medical Cannabis Strain Selection
End 3Q 2017: Further Insights into the Patient Medical Cannabis Evaluation
End 4Q 2017: Preliminary Conclusions from the Launch of The Dosing Project™